Browse by Medical Category
Particularly interested in breast cancer, Dr. Baselga has been deeply involved in the development of new targeted therapies that attack cancer at the molecular level.
Using two drugs that inhibit the growth factor HER2 for preoperative treatment of early-stage HER2-positive breast cancer appears to have better results than treatment with a single agent.
Two New England Journal of Medicine papers reporting the results of separate Phase III clinical trials for the treatment of advanced breast cancer recently received early, online first release because the studies were presented at the December 2011 CTRC-AACR San Antonio Breast Cancer Symposium.
Cancer Center Associate Director and Chief of Hematology/Oncology José Baselga, MD, PhD, continues our quest to bring the most promising targeted therapies from the bench to the bedside.
MGH Hotline 12.10.10 A named chair is one of the highest honors a physician may receive in his or her lifetime.
Back to Top